Chester County News and Community Website
WARMINSTER, PA — Arbutus Biopharma Corp. (Nasdaq: ABUS) expects to return as much as $230 million to shareholders after receiving about $178 million from Moderna, while expanding its patent litigation …
Arbutus Plans $230M Buyback as Patent Fight Expands Read More WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) reported a sharp swing to quarterly profit after recognizing revenue tied to a patent litigation settlement involving Moderna, while also receiving FDA …
Arbutus Posts Profit After Moderna Patent Settlement Read More WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) announced that the U.S. Food and Drug Administration has granted Fast Track designation to its drug candidate imdusiran for the treatment of …
Arbutus Drug Candidate Receives FDA Fast Track Designation Read More WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) recently reported its fourth-quarter and full-year 2025 results and disclosed a global settlement with Moderna valued at up to $2.25 billion, the …
Arbutus Reports Results, Announces $2.25B Moderna Settlement Read More
WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) reported third quarter 2025 financial results and released new analyses showing sustained, long-term therapeutic benefit from its chronic hepatitis B candidate imdusiran …
Arbutus Reports Major Advances in HBV Candidate as Litigation Against Moderna, Pfizer Builds Toward Trial Read More WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) announced that four abstracts have been accepted for presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver …
Arbutus Biopharma to Present New Data on Imdusiran and AB-101 at AASLD 2025 Read More WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) reported a return to profitability in the second quarter, driven by the termination of a regional licensing deal and renewed strategic focus on …
Arbutus Biopharma Returns to Profitability as It Regains Global Rights to Lead Hepatitis B Drug Read More WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) announced it has reacquired full global rights to its lead RNAi compound, imdusiran, following the conclusion of its strategic partnership with Qilu …
Arbutus Biopharma Reacquires China Rights to Imdusiran, Forms Scientific Advisory Board Read More WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS), a key player in advancing treatments for chronic hepatitis B (cHBV), outlined its progress in Q1 2025, showcasing pivotal clinical milestones, financial …
Arbutus Biopharma Reports Q1 2025 Results, Clinical Developments, and Legal Progress Read More WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) recently presented compelling data on its investigational hepatitis B therapies, imdusiran and AB-101, at the European Association for the Study of the …
Arbutus Biopharma Showcases Promising Results for Hepatitis B Therapies at EASL Congress 2025 Read More